{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T04:44:48Z","timestamp":1744173888215},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":3011,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2000,11]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item>\n<jats:p>The effect of the novel ET<jats:sub>A<\/jats:sub> receptor antagonist LBL 031 and other selective and mixed endothelin receptor antagonists on endothelin\u20101 (ET\u20101)\u2010induced and lipopolysaccharide (LPS)\u2010induced microvascular leakage was assessed in rat airways<\/jats:p>\n<\/jats:list-item>\n<jats:list-item>\n<jats:p>Intravenously administered ET\u20101 (1\u2003nmole\u2003kg<jats:sup>\u22121<\/jats:sup>) or LPS (30\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) caused a significant increase in microvascular leakage in rat airways when compared to vehicle treated animals.<\/jats:p>\n<\/jats:list-item>\n<jats:list-item>\n<jats:p>Pre\u2010treatment with the selective ET<jats:sub>A<\/jats:sub> receptor antagonists, LBL 031 or PD 156707, or the mixed ET<jats:sub>A\/B<\/jats:sub> receptor antagonist, bosentan (each at 30\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>), reduced ET\u20101\u2010induced leakage to baseline levels. ET\u20101\u2010induced leakage was not reduced by pre\u2010treatment with the ET<jats:sub>B<\/jats:sub> selective antagonist BQ 788 (3\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>).<\/jats:p>\n<\/jats:list-item>\n<jats:list-item>\n<jats:p>Pre\u2010treatment with the selective ET<jats:sub>A<\/jats:sub> receptor antagonist, LBL 031 (0.1\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) or PD 156707 (10\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>), or the mixed ET<jats:sub>A\/B<\/jats:sub> receptor antagonist, bosentan (30\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>), reduced LPS\u2010induced leakage by 54, 48 and 59% respectively. LPS\u2010induced leakage was not affected by pre\u2010treatment with the ET<jats:sub>B<\/jats:sub> selective antagonist BQ 788 (3\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>).<\/jats:p>\n<\/jats:list-item>\n<jats:list-item>\n<jats:p>The data suggests that ET\u20101\u2010induced microvascular leakage in the rat airway is ET<jats:sub>A<\/jats:sub> receptor mediated and that part of the increase induced by LPS may be due to the actions of ET\u20101. Therefore, a potent ET<jats:sub>A<\/jats:sub> receptor selective antagonist, such as LBL 031, may provide a suitable treatment for inflammatory diseases of the airways, especially those involving LPS and having an exudative phase, such as the septic shock\u2010induced adult respiratory distress syndrome.<\/jats:p>\n<\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2000) <jats:bold>131<\/jats:bold>, 1129\u20131134; doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0703691\">10.1038\/sj.bjp.0703691<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0703691","type":"journal-article","created":{"date-parts":[[2005,1,28]],"date-time":"2005-01-28T21:00:40Z","timestamp":1106946040000},"page":"1129-1134","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of endothelin antagonists, including the novel ET<sub>A<\/sub> receptor antagonist LBL 031, on endothelin\u20101 and lipopolysaccharide\u2010induced microvascular leakage in rat airways"],"prefix":"10.1111","volume":"131","author":[{"given":"Dave J","family":"Hele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A","family":"Birrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E","family":"Webber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martyn L","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G","family":"Belvisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)00116-1"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm990378b"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.155.3.9117019"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.11.4.7917311"},{"key":"e_1_2_6_6_1","first-page":"228","article-title":"Pharmacological characterisation of Bosentan, a new potent orally active nonpeptide endothelin receptor antagonist","volume":"270","author":"CLOZEL M.","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1996.81.4.1510"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(93)90131-L"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb17070.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.152.5.7582310"},{"key":"e_1_2_6_11_1","first-page":"158P","article-title":"The effect of endothelin antagonists on endothelin\u20101 and lipopolysaccharide\u2010induced microvascular leakage in the rat airways","volume":"126","author":"HELE D.J.","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.11.4892"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1646"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09122650"},{"key":"e_1_2_6_15_1","first-page":"485","article-title":"Causes of mortality in patients with the adult respiratory distress syndrome","volume":"132","author":"MONTGOMERY A.B.","year":"1985","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_6_16_1","first-page":"199","article-title":"Pathophysiologic role of endothelin\u20101 in renal function in rats with endotoxin shock","volume":"115","author":"MORISE Z.","year":"1994","journal-title":"Surgery"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/138.3.720"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.18.5.2898"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15385.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.2.9607123"},{"key":"e_1_2_6_21_1","first-page":"1410","article-title":"Pharmacological characterisation of PD 156707, an orally active ETA receptor antagonist","volume":"273","author":"REYNOLDS E.E.","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01728331"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.48.4.330"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(98)00003-X"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90352-I"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/332411a0"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0703691","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0703691","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0703691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T15:29:14Z","timestamp":1695828554000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0703691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["10.1038\/sj.bjp.0703691"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0703691","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,11]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}